Turbinate Hypertrophy, Allergic Rhinitis, and Otitis Media.

Allergic rhinitis Otitis media Real-life setting Turbinate hypertrophy Type 2 inflammation

Journal

Current allergy and asthma reports
ISSN: 1534-6315
Titre abrégé: Curr Allergy Asthma Rep
Pays: United States
ID NLM: 101096440

Informations de publication

Date de publication:
30 09 2021
Historique:
accepted: 04 06 2021
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 26 11 2021
Statut: epublish

Résumé

Otitis media (OM) is a disease with high prevalence in infancy; it has a substantial burden on healthcare resources, and a relevant impact on the quality of life of families. The link between OM and allergic rhinitis (AR) is still debated. However, there is agreement about the relevance of type 2 inflammation on turbinate hypertrophy (TH) generation. There is also evidence that TH is associated with middle ear dysventilation: a pathogenic factor promoting OM. Therefore, a vicious circle among AR, TH, and OM may occur. There are some recent studies exploring this issue through different approaches, such as epidemiological, mechanistic, and therapeutic. Identifying allergy as a pathogenic factor for OM could improve the management of OM patients. Vice versa, suspecting AR in OM patients, could be reasonable in selected patients. The current narrative review provides an overview of the evidence concerning the potential role of AR, and associated TH, in OM patients.

Identifiants

pubmed: 34591196
doi: 10.1007/s11882-021-01021-y
pii: 10.1007/s11882-021-01021-y
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Giorgio Ciprandi (G)

Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy. gio.cip@libero.it.

Maria Angela Tosca (MA)

Allergy Center, Istituto Giannina Gaslini, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH